2025
FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniques.
Payabvash S, Sharaf K, Zeevi T, Gross M, Mahajan A, Kann B, Judson B, Schreier A, Krenn J, Prasad M, Burtness B, Aboian M, Canis M, Baumeister P, Reichel C, Haider S. FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniques. American Journal Of Neuroradiology 2025, ajnr.a8836. PMID: 40379456, DOI: 10.3174/ajnr.a8836.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaStandardized uptake valueSquamous cell carcinomaFDG-PETRadiomic featuresPET featuresOncological outcomesLentiform nucleusCell carcinomaUptake valuePrognostic value of radiomics featuresC-indexOropharyngeal squamous cell carcinoma patientsValue of radiomic featuresProgression-free survivalOropharyngeal cancer patientsUnivariate Cox regression modelPredicting oncological outcomesRandom survival forestArea under the curveHarrell's concordance indexIndividual radiomics featuresStandardized uptake ratioHarrell's C-indexCox regression models
2024
Reproducibility of Semi-automated Quantitative Analyses of Tc-99m Pyrophosphate Uptake from Myocardial Perfusion Planar and SPECT Images
Goyal D, Sandoval V, Weyman C, Miller E, Liu Y. Reproducibility of Semi-automated Quantitative Analyses of Tc-99m Pyrophosphate Uptake from Myocardial Perfusion Planar and SPECT Images. Journal Of Medical And Biological Engineering 2024, 45: 84-91. DOI: 10.1007/s40846-024-00924-1.Peer-Reviewed Original ResearchStandardized uptake valueTc-99SPECT imagesStandard uptake value quantificationTransthyretin cardiac amyloidosisH/CL ratioTc-99m PYP uptakeMethodsOur study cohortInter-observer reproducibilityPlanar imagingTechnetium-99mCardiac amyloidosisClinical suspicionSPECT/CT imagingTc-99m PYP imagingTc-99m PYPConsecutive subjectsUptake valueObserver reproducibilityStudy cohortInter-observerPurposeThe aimResultsIntra-observerMyocardial uptakeSPECTClinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S, Rocco G, Chaft J, Iyengar P, Gomez D, Adusumilli P, Park B, Isbell J, Bott M, Sihag S, Molena D, Huang J, Jones D. Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma. JTCVS Open 2024, 22: 458-469. PMID: 39780816, PMCID: PMC11704575, DOI: 10.1016/j.xjon.2024.09.030.Peer-Reviewed Original ResearchResection of lung adenocarcinomaMaximum standardized uptake valueDevelopment of brain metastasesBrain metastasesStandardized uptake valueNeoadjuvant therapyLung adenocarcinomaAssociated with developmentLymphovascular invasionTP53 mutationsUptake valueCumulative incidence of brain metastasesMarker of aggressive tumor biologyHighest maximum standardized uptake valueLack of extracranial metastasesIncidence of brain metastasesNext-generation sequencingPanel next-generation sequencingAssociated with better survivalStage III diseaseMedian Follow-UpAggressive tumor biologyBetter performance statusAssociated with brain metastasisStereotactic radiosurgeryReproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients
Sandoval V, Goyal D, Miller E, Liu Y. Reproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients. European Heart Journal - Cardiovascular Imaging 2024, 25: jeae142.047. DOI: 10.1093/ehjci/jeae142.047.Peer-Reviewed Original ResearchStandardized uptake valueTc-99m PYP uptakeTc-99Cardiac amyloidosisHeart failureStandard uptake value quantificationStandardized uptake value calculationSPECT imagesIntractable heart failureSystolic heart failureIntroduction of therapyPlanar imagingTc-99m pyrophosphateAmyloid patientsSPECT/CT imagingInter-reproducibilityUptake valueContralateral ratioCoefficient of variationDisease progressionH/M ratioGrade 1Blood poolPatientsH/CL ratio
2023
Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans
Kirk F, Munk D, Swenson E, Quicquaro A, Vendelbo M, Schilsky M, Ott P, Sandahl T. Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans. Hepatology 2023, 79: 1065-1074. PMID: 38088886, PMCID: PMC11019997, DOI: 10.1097/hep.0000000000000708.Peer-Reviewed Original ResearchUrinary copper excretionStandard uptake valueIntestinal copper absorptionUptake valueCopper excretionIntestinal absorptionPositron emission tomography/CT scanMean standard uptake valueSame therapeutic targetsPET/CT studiesVenous blood samplesCopper absorptionIntestinal copper uptakeEffects of drugsUrinary excretionCT scanHealthy volunteersBlood samplesHealthy humansTrientineTherapeutic targetBody weightCT studiesWilson's diseaseD-penicillamine
2022
Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake
Fu J, Lois C, Sanchez J, Becker J, Rubinstein Z, Thibault E, Salvatore A, Sari H, Farrell M, Guehl N, Normandin M, Fakhri G, Johnson K, Price J. Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake. Cerebrovascular And Brain Metabolism Reviews 2022, 43: 581-594. PMID: 36420769, PMCID: PMC10063833, DOI: 10.1177/0271678x221142139.Peer-Reviewed Original ResearchConceptsPartial volume correctionLongitudinal changesReference regionStandardized uptake valueFollow-up scansExtracerebral signalsAssessment of longitudinal changesCross-sectional effect sizesUptake valuePET uptakeDistribution volumeRegional uptakeArterial samplesExtracerebral contaminationOne-yearCognitively-normalEffect sizePonsGroup differentiationVolume correctionSubject levelSubjects191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)
Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026). Annals Of Oncology 2022, 33: s623-s624. DOI: 10.1016/j.annonc.2022.07.226.Peer-Reviewed Original ResearchBiodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1
Rischka L, Murgaš M, Pichler V, Vraka C, Rausch I, Winkler D, Nics L, Rasul S, Silberbauer LR, Reed MB, Godbersen GM, Unterholzner J, Handschuh P, Gryglewski G, Mindt T, Mitterhauser M, Hahn A, Ametamey SM, Wadsak W, Lanzenberger R, Hacker M. Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1. EJNMMI Research 2022, 12: 53. PMID: 36018389, PMCID: PMC9418393, DOI: 10.1186/s13550-022-00925-8.Peer-Reviewed Original ResearchExtrasynaptic NMDA receptorsStandardized uptake valueNMDA receptorsUrinary bladderEffective dose coefficientsPET radioligandNeuropsychiatric disordersTreatment monitoringSynaptic NMDA receptorsTime-integrated activity coefficientsCentral nervous systemUrinary bladder contentsDrug developmentDose coefficientsAdverse eventsExcitotoxic processTRIAL REGISTRATIONBladder contentsHealthy subjectsSynaptic transmissionSide effectsBone marrowNervous systemUptake valueEffective dose[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change
2021
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology 2021, 39: 2247-2256. PMID: 33999652, PMCID: PMC8260904, DOI: 10.1200/jco.21.00280.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoadjuvant TherapyPositron Emission Tomography Computed TomographyPredictive Value of TestsRadiopharmaceuticalsReceptor, ErbB-2Time FactorsTrastuzumabTreatment OutcomeUnited StatesConceptsPositron emission tomography-computed tomographyFluorodeoxyglucose positron emission tomography-computed tomographyHER2-positive breast cancerEmission tomography-computed tomographyPathologic complete responseTomography-computed tomographyStandardized uptake valueBreast cancerComplete responseUptake valuePercent changeOne-sided type ITumor maximum standardized uptake valueHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Maximum standardized uptake valuePathological complete responseGrowth factor receptor 2Median percent reductionPositive breast cancerTailoring of therapyLean body massReceiver operator characteristic analysisFactor receptor 2Operator characteristic analysisPreoperative Texture Analysis Using 11C-Methionine Positron Emission Tomography Predicts Survival after Surgery for Glioma
Manabe O, Yamaguchi S, Hirata K, Kobayashi K, Kobayashi H, Terasaka S, Toyonaga T, Magota K, Kuge Y, Tamaki N, Shiga T, Kudo K. Preoperative Texture Analysis Using 11C-Methionine Positron Emission Tomography Predicts Survival after Surgery for Glioma. Diagnostics 2021, 11: 189. PMID: 33525709, PMCID: PMC7911154, DOI: 10.3390/diagnostics11020189.Peer-Reviewed Original ResearchPositron emission tomographyOverall survivalEmission tomographyMET positron emission tomographyWorld Health Organization classificationMean standardized uptake valuePreoperative metabolic imagingPreoperative texture analysisMalignant brain tumorsStandardized uptake valueCause deathLow gray-level run emphasisContralateral cortexMET uptakeSingle centerPrognostic valueGrade IIIOrganization classificationTumor gradeUnivariate analysisGrade IIGrade IVBrain tumorsUptake valueSurvival curves
2020
Accuracy of arterial [18F]-Fluorodeoxyglucose uptake quantification: A kinetic modeling study
Toczek J, Wu J, Hillmer AT, Han J, Esterlis I, Cosgrove KP, Liu C, Sadeghi MM. Accuracy of arterial [18F]-Fluorodeoxyglucose uptake quantification: A kinetic modeling study. Journal Of Nuclear Cardiology 2020, 27: 1578-1581. PMID: 32043239, PMCID: PMC7415600, DOI: 10.1007/s12350-020-02055-x.Peer-Reviewed Original ResearchConceptsMean SUVmaxMean TBRmaxFDG signalAortic wallMaximal standardized uptake valueD-glucose (FDG) PETVessel wall inflammationStandardized uptake valueActivity ex vivoPET imaging agentVascular inflammationWall inflammationRecent guidelinesBlood ratioCardiovascular diseasePrior historyPlasma activityTracer uptakeUptake valueSUVmaxTBRmaxEx vivoArterial wallVascular imagingFDG
2019
Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h
Kobayashi K, Manabe O, Hirata K, Yamaguchi S, Kobayashi H, Terasaka S, Toyonaga T, Furuya S, Magota K, Kuge Y, Kudo K, Shiga T, Tamaki N. Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 47: 1833-1842. PMID: 31781832, DOI: 10.1007/s00259-019-04626-8.Peer-Reviewed Original ResearchConceptsStandardized uptake valueWhite matter ratioWhite matterGray matterMean standardized uptake valueMethodsTwenty-three patientsScan time pointsPositron emission tomography (PET) tracerEmission tomography tracerMaximum tumorIntravenous injectionResultsAt 2Single injectionBrain tumorsUptake valueBrain tissueTumor hypoxiaTumorsTomography tracerTime pointsHypoxia imagingNormal ratioHypoxic tumorsPatientsSUVmaxTBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology 2019, 37: jco.2018.78.7986. PMID: 30721110, PMCID: PMC6424139, DOI: 10.1200/jco.2018.78.7986.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingPredictive Value of TestsRadiopharmaceuticalsReceptor, ErbB-2Receptors, EstrogenSingle Photon Emission Computed Tomography Computed TomographyTime FactorsTrastuzumabTreatment OutcomeUnited StatesConceptsPathologic complete responseHER2-positive breast cancerPositron emission tomography/Emission tomography/Standardized uptake valueBreast cancerComplete responseTomography/Uptake valueTumor maximum standardized uptake valueOne-sided type IHuman epidermal growth factor receptor 2Stage II/IIIEpidermal growth factor receptor 2Maximum standardized uptake valueCycles of PTGrowth factor receptor 2Median percent reductionPositive breast cancerLean body massFactor receptor 2Significant differencesEvaluable patientsNeoadjuvant pertuzumabPT initiation
2018
[18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Verwer E, Kavanagh T, Mischler W, Feng Y, Takahashi K, Wang S, Shoup T, Neelamegam R, Yang J, Guehl N, Ran C, Massefski W, Cui Y, El-Chemaly S, Sadow P, Oldham W, Kijewski M, Fakhri G, Normandin M, Priolo C. [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM. Clinical Cancer Research 2018, 24: 5925-5938. PMID: 30054282, PMCID: PMC6816044, DOI: 10.1158/1078-0432.ccr-17-3693.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsBiomarkersCholineDisease Models, AnimalFemaleFluoroacetatesHeterograftsHumansImage Processing, Computer-AssistedImmunohistochemistryLipid MetabolismLymphangioleiomyomatosisMaleMiceMice, TransgenicMitochondriaOxygen ConsumptionPhosphatidylcholinesPositron-Emission TomographyRatsTuberous SclerosisConceptsTuberous sclerosis complexMetabolic imaging biomarkersPreclinical modelsImaging biomarkersTSC2-deficient cellsStandardized uptake valueTuberous sclerosis complex manifestationsModels of tuberous sclerosis complexAutosomal dominant disorderPotential clinical interestBenign tumorsOvariectomized miceUptake valueSubcutaneous tumorsPreclinical studiesPulmonary nodulesCystic destructionLymphangioleiomyomatosisDominant disorderProliferative lesionsInactivating mutationsTumorMetabolic reprogrammingNeurocognitive impairmentPET imagingSynthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates
Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, Gao H, Labaree D, Nabulsi N, Carson RE, Huang Y. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chemical Neuroscience 2018, 10: 1544-1554. PMID: 30396272, PMCID: PMC6810685, DOI: 10.1021/acschemneuro.8b00526.Peer-Reviewed Original ResearchConceptsSynaptic vesicle glycoprotein 2AStandardized uptake valuePET radiotracersNonhuman primatesAlterations of synapsesC-UCBPeak standardized uptake valueVivo evaluationHigh brain uptakeNovel PET radiotracersBrain uptakeSynaptic densityExcellent radiotracerPsychiatric disordersUptake valueCingulate cortexAlzheimer's diseaseBrain disordersNovel radiotracersRhesus monkeysNeurodegenerative diseasesTissue kineticsDiseaseAttractive imaging propertiesLevetiracetamImproved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodulesRadiotracer Imaging Allows for Noninvasive Detection and Quantification of Abnormalities in Angiosome Foot Perfusion in Diabetic Patients With Critical Limb Ischemia and Nonhealing Wounds
Alvelo JL, Papademetris X, Mena-Hurtado C, Jeon S, Sumpio BE, Sinusas AJ, Stacy MR. Radiotracer Imaging Allows for Noninvasive Detection and Quantification of Abnormalities in Angiosome Foot Perfusion in Diabetic Patients With Critical Limb Ischemia and Nonhealing Wounds. Circulation Cardiovascular Imaging 2018, 11: e006932. PMID: 29748311, PMCID: PMC5951395, DOI: 10.1161/circimaging.117.006932.Peer-Reviewed Original ResearchMeSH KeywordsAnkle Brachial IndexCase-Control StudiesCritical IllnessDiabetic FootHumansIschemiaMicrocirculationOrganophosphorus CompoundsOrganotechnetium CompoundsPerfusion ImagingPredictive Value of TestsRadiopharmaceuticalsRegional Blood FlowSingle Photon Emission Computed Tomography Computed TomographyWound HealingConceptsCritical limb ischemiaAnkle-brachial indexStandardized uptake valueSPECT/CT imagingDiabetic patientsHealthy subjectsSPECT/CTFoot perfusionUptake valueLimb ischemiaMicrovascular perfusionSkeletal muscle microvascular perfusionCT imagingDiabetic CLI patientsMuscle microvascular perfusionPeripheral artery diseaseSingle photon emissionIntraclass correlation coefficientAngiosome perfusionCLI subjectsCLI patientsArtery diseaseDiabetes mellitusCT perfusionVascular territoriesEvaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes
Naganawa M, Lim K, Nabulsi NB, Lin SF, Labaree D, Ropchan J, Herold KC, Huang Y, Harris P, Ichise M, Cline GW, Carson RE. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes. Molecular Imaging And Biology 2018, 20: 835-845. PMID: 29468404, PMCID: PMC6533199, DOI: 10.1007/s11307-018-1170-6.Peer-Reviewed Original ResearchConceptsVesicular monoamine transporter type 2Non-displaceable uptakeHealthy controlsSUV ratioType 1 diabetes mellitus groupInactive enantiomerDiabetes mellitus groupBeta-cell massFirst human studyGroup differencesPositron emission tomography (PET) radiotracerTransporter type 2Mellitus groupVT valuesSignificant group differencesT1DM patientsRenal cortexHealthy subjectsPurposePrevious studiesHuman studiesUptake valueType 2Separate daysDistribution volumeReference SUV
2017
Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database
Korst RJ, Fernando S, Catlin AC, Rutledge JR, Girard N, Huang J, Detterbeck F, Database C. Positron Emission Tomography in Thymic Tumors: Analysis Using a Prospective Research Database. The Annals Of Thoracic Surgery 2017, 104: 1815-1820. PMID: 29033016, PMCID: PMC5785101, DOI: 10.1016/j.athoracsur.2017.06.053.Peer-Reviewed Original ResearchConceptsPositron emission tomographyInternational Thymic Malignancy Interest GroupHistologic typeThymic malignanciesPretreatment workupPathologic stageEmission tomographyProspective databaseThymic tumorsTumor stageMaximum standardized uptake valueProspective research databaseHistologic tumor typeThymic epithelial tumorsStandardized uptake valueCharacteristic curveAnalysis of receiverClinicopathologic featuresRare tumorEpithelial tumorsLarge cohortResearch DatabaseUptake valueTumor typesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply